Increased hsCRP an indicator for residual risk after MI Dr. Kamal Kant Kohli Kohli2 April 2018 7:31 PM ISTThe data in CANTOS supported the inflammatory hypothesis of atherothrombosis but it remains uncertain which patients benefit the most from...
Anti-inflammatory drugs not yet for Atherosclerosis-ESC Consensus statement Dr. Kamal Kant Kohli Kohli14 May 2018 8:00 PM ISTEuropean Society of Cardiology (ESC) has released its latest consensus statement on inflammation in atherosclerosis which has been published in the...
Fremanezumab effective in prevention of episodic migraine : JAMA Medha Baranwal Baranwal19 May 2018 8:30 PM ISTIn patients with an episodic migraine, administration of subcutaneous fremanezumab compared with placebo resulted in a reduction in the mean number of...
Guselkumab safe,effective in patients with active psoriatic arthritis Vinay Singh singh10 Jun 2018 7:10 PM ISTProf. Atul Deodhar and his associates conducted a study to assess the efficacy and safety of guselkumab in patients with active psoriatic arthritis....
Canakinumab reduces gout flares by more than half in atherosclerosis19 Vinay Singh singh4 July 2018 7:10 PM ISTCanakinumab significantly reduced the rate of gout by more than half among patients with atherosclerosis, according to the findings of the research...
Refusal to canakinumab for secondary prevention -- Treatment of residual risk faces a roadblock Medha Baranwal Baranwal7 March 2019 8:28 PM ISTThe fight against the residual cardiovascular risk after myocardial infarction by targeting inflammation by anti-inflammatory drug faces a roadblock....
Clinical Trial finds novel treatment of rare form of psoriasis Hina Zahid11 March 2019 7:20 PM ISTRIDGEFIELD, Conn. -- New data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved...
Erenumab - a promising drug for chronic migraine associated with medication overuse Medha Baranwal Baranwal19 May 2019 7:30 PM ISTUSA: A phase 2 trial showed Erenumab to be a promising drug for patients with chronic migraine (CM) and medication overuse. Erenumab is a fully human...
Temelimab -A promising disease-modifying therapy for patients with type 1 diabetes Medha Baranwal Baranwal20 May 2019 8:10 PM ISTTemelimab, a monoclonal antibody, is an upcoming promising treatment for patients with type 1 diabetes (T1D) or juvenile diabetes, suggests evidence...
PCSK9 inhibitor Alirocumab effectively reduces high LDL-C in Type 2 Diabetes patients Deepanjana Sarkar6 Aug 2019 8:20 PM ISTAlirocumab (a PCSK9 inhibitor) 300 mg for 4 Weeks in Type 2 diabetes patients reduces low-density lipoprotein cholesterol effectively, revealed a...
Intravenous eptinezumab may prevent migraine for 3 months confirms phase 3 trial Medha Baranwal Baranwal14 Aug 2019 8:27 PM ISTUSA: Intravenous eptinezumab, an anti‐CGRP (calcitonin gene-related peptide) monoclonal antibody, showed efficacy for the prevention of chronic...
